Table 3.
Association between 5-ARI use and lethal prostate cancer and total mortality in men with localized or locally advanced prostate cancer at diagnosis (n=4,383), 1996–2019
| Number of Events | Age-adjusted HR (95% CI) | Model 1 adjusted HR (95% CI)1 | Model 2 adjusted HR (95% CI)2 | |
|---|---|---|---|---|
|
| ||||
| Lethal prostate cancer3 | 320 | |||
| Ever use of 5-ARIs | 19 | 1.03 (0.65, 1.65) | 0.73 (0.45, 1.18) | 0.78 (0.48, 1.27) |
| < 4 years of use | 13 | 1.30 (0.74, 2.26) | 1.05 (0.60, 1.85) | 1.11 (0.63, 1.96) |
| ≥ 4 years of use | 6 | 0.71 (0.32, 1.61) | 0.44 (0.19, 0.99) | 0.46 (0.20, 1.06) |
|
| ||||
| Total mortality (including lethal prostate cancer)4 | 1899 | |||
| Ever use of 5-ARIs | 107 | 0.96 (0.79, 1.17) | 0.87 (0.71, 1.06) | 0.88 (0.72, 1.07) |
| < 4 years of use | 57 | 0.91 (0.70, 1.18) | 0.85 (0.65, 1.11) | 0.85 (0.65, 1.11) |
| ≥ 4 years of use | 50 | 1.03 (0.78, 1.37) | 0.89 (0.67, 1.19) | 0.91 (0.69, 1.22) |
1
adjusted for stage at diagnosis, Gleason grade, and age at diagnosis
2
adjusted for everything in model 1 and BMI, family history of prostate cancer, PSA at diagnosis, activity level, smoking status at diagnosis, and race
3
defined as prostate cancer death or distant metastases over follow-up
4
defined as death from any cause or distant prostate cancer metastases